Neuberger Berman Group
HRTX icon

Neuberger Berman Group’s Heron Therapeutics HRTX Stock Holding History

Neuberger Berman Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-26,500
Closed -$1.03M – 1654
2018
Q2 		$1.03M Buy
+26,500
New +$844K ﹤0.01% 1224

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Neuberger Berman Group's HRTX Position: Q3 2018 in Review

Neuberger Berman Group sold out of Heron Therapeutics (HRTX) in Q3 2018, closing a stake of 26,500 shares — an estimated $1.03M sold.

Neuberger Berman Group first reported a position in HRTX in Q2 2018 and held it in 1 quarter. The position peaked at $1.03M in Q2 2018. 194 funds tracked by Wall St. Rank hold HRTX as of Q3 2018.

  • Neuberger Berman Group reported no remaining Heron Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 26,500 Heron Therapeutics shares in Q3 2018, an estimated $1.03M.
  • Neuberger Berman Group first reported a position in Heron Therapeutics in Q2 2018 and held it in 1 quarter.
  • Neuberger Berman Group's Heron Therapeutics position peaked at $1.03M in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2018.

Based on Neuberger Berman Group's 13F filing for Q3 2018, filed 13 Nov 2018.